Shares of Viyash Scientific Ltd. rose nearly 7% on Monday after reports said promoter Carlyle could sell up to a 10% stake in the company.
The stock hit an intraday high of Rs 305.45, compared with the previous close of Rs 254.55. Viyash Scientific has a market value of Rs 11,852 crore. The stock has gained 47% over the past year.
Reported stake sale draws attention
Sources said Carlyle is considering a sale of around 10% in the company.
Carlyle currently owns 61.3% of Viyash Scientific and is the promoter. Reports linked the proposed sale to Carlyle’s investment in Viyash Scientific, which was consolidated with Sequent Scientific.
Interest is said to be coming from:
- Mutual fund houses
- Strategic investors
Earlier, promoter ownership had increased from 53% to 61.3% through CA Harbor Investments and CA Hull Investments.
The ownership structure changed during Q4 FY26.
- Promoter holding: 61.31%, up from 52.61% a year earlier
- FII holding: 2.94%, down from 6.05%
- DII holding: 7.98%, compared with 12.82%
- Public shareholding: 27.67%, against 28.36%
- Other category: 0.09%
Business profile
Viyash Scientific Ltd., formerly known as Sequent Scientific Limited, is based in Hyderabad.
The company operates in both human and animal healthcare markets. Its businesses include:
- Active Pharmaceutical Ingredients (APIs)
- Advanced intermediates
- Finished Drug Formulations (FDFs)
Quarterly performance
The company reported strong growth in the March quarter.
Revenue from operations
- Q4 FY26: Rs 920 crore
- Q4 FY25: Rs 402 crore
- Growth: 129%
EBIDT
- Q4 FY26: Rs 184 crore
- Q4 FY25: Rs 46.2 crore
- Growth: 298%
Net profit
- Q4 FY26: Rs 66.4 crore
- Q4 FY25: Rs 10.4 crore
- Growth: 455%
Earnings per share
- Q4 FY26: Rs 1.19
- Q4 FY25: Rs 0.37
- Growth: 222%
The stock gained momentum after reports of the proposed stake sale, with investors watching for possible participation from institutional buyers.
TL;DR:
Viyash Scientific shares climbed nearly 7% after reports said promoter Carlyle may sell up to a 10% stake. The private equity firm holds 61.3% of the company, and the proposed sale has reportedly drawn interest from mutual funds and strategic investors.
AI summary:
- Viyash Scientific shares rose 6.9% on Monday.
- Reports said Carlyle may sell a 10% stake.
- Carlyle currently holds 61.3% of the company.
- Mutual funds and strategic investors are said to be interested.
- Revenue, profit and earnings rose sharply in Q4 FY26.
